MedPath

Incretin Effect in Lean and Obese Subjects

Completed
Conditions
Incretin Effect
Insulin Resistance
Type 2 Diabetes
Registration Number
NCT00803296
Lead Sponsor
University Hospital, Gentofte, Copenhagen
Brief Summary

The incretin effect is markedly reduced in patients with type 2 diabetes. Data support the notion that this deficiency is a consequence of the diabetic state. However, the impact of insulin resistance on the incretin effect in obese individuals who uphold a normal glucose tolerance (NGT) despite their insulin resistant state remains to be elucidated. The primary aim of the present study is to evaluate the separate impact of one of the cornerstones of type 2 diabetic pathophysiology, namely insulin resistance, on the incretin effect in lean and obese patients with type 2 diabetes and in two matched normal-glucose tolerant groups of healthy control subjects.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
32
Inclusion Criteria
  • Diagnosed with type 2 diabetes for at least 3 months
  • Normal blood hemoglobin
  • Informed consent
Exclusion Criteria
  • Liver disease
  • Diabetic nephropathy
  • Treatment with medication that can not be stopped for 12 hours

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incretin effect2 days
Secondary Outcome Measures
NameTimeMethod
Insulin resistance2 days

Trial Locations

Locations (1)

Gentofte Hospital, University of Copenhagen

🇩🇰

Hellerup, Copenhagen, Denmark

Gentofte Hospital, University of Copenhagen
🇩🇰Hellerup, Copenhagen, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.